ENDO-LANDSCAPENCT05547607
Clinical and Diagnostic Features of Endocarditis
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 4 words Show 5 more changesShow less
- Trial completed
- Final enrollment: 938 participants (planned 500)
- Primary completion date changed from estimate of Jun 30, 2026 to Nov 4, 2026
- Site details revised
- Publications: details revised at 1 of 1 entry
- Notable Primary completion date: Sep 30, 2025 to Jun 30, 2026
- Study completion date: Sep 30, 2026 to Jun 30, 2028
- Notable Primary completion date: Sep 30, 2024 to Sep 30, 2025
- Study completion date: Sep 30, 2025 to Sep 30, 2026
- Minor Secondary endpoints: details revised at 1 of 5 entriesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (5)
Arms and interventions
All consecutive patients referred for an echocardiography (transthoracic or transesophageal approach) with a high suspicion of endocarditis and those with a confirmed diagnosis of endocarditis independently by the request will be eligible for the study.
For patients with no evidence of endocarditis on their echocardiogram, data on the following will be collected: i) risk factors for endocarditis; i) size, type and position of valve prosthesis or other devices if present; iii) Duke criteria verification.
Diagnostic tests: advanced cardiac imaging
Sites
1 site in 1 country
- University Hospital of FerraraCona, Ferrara, Italy